Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentration of alpha-fetoprotein (AFP) rises greatly in patients with liver cancer and it is a challenge to construct a sensitive AFP detection method with wide range.
|
31761168 |
2020 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The detection rate of AFP for liver cancer was 86.8%, and the exclusive diagnostic rate of AFP for hepatic FNH was 96.9%.
|
31646787 |
2020 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma Hsp90α maintains also broad-spectrum for cancer subtypes, especially with 91.78% sensitivity and 91.96% specificity in patients with AFP-limited liver cancer.
|
31343810 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One-shot transfusion of hepatoma serum to naïve rats induced liver cancer development with gradual elevation of alpha-fetoprotein (AFP), but exosome-free hepatoma serum failed to induce AFP elevation.
|
31162867 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a 32-gene diagnostic model that accurately distinguished early HCC (stage 0/A) based on the Barcelona Clinic Liver Cancer staging system from non-HCC (validation set: area under curve (AUC)=88.4%; (95% CI 85.8% to 91.1%)), showing superior performance over α-fetoprotein (AFP).
|
31358576 |
2019 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, the increased serum AFP levels were most evident but not specific for liver cancer patients.
|
30905450 |
2019 |
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using multivariate Cox regression analyses, the patient-related eGFRcre/eGFRcys ratio (hazard ratio [HR], 4.178; P = 0.007), as well as the tumor-related factors α-fetoprotein (HR, 1.000; P < 0.001) and Barcelona Clinic Liver Cancer stage (HR, 2.589; P < 0.001), were independent predictors of survival.
|
30005446 |
2019 |
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of clinicopathologic analysis showed that A allele at the rs737241 locus could increase the expression level of AFP (P = .007), the rs1046282 mutation C allele could increase the AFP expression level (P = .011), rs4024 locus mutation A allele could reduce the risk of vascular invasion (P = .013), rs3212948 locus mutation T allele could reduce the differentiation of liver cancer (P = .022), rs1046282 locus C allele could reduce the DNA load of hepatitis B virus (P = .035), and rs735482 A allele could increase the tumor size in HCC (P = .037).The SNPs in rs737241 for AFP gene may correlate with the occurrence of HCC.
|
30946366 |
2019 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Only alpha-fetoprotein levels predicted the probability of cure among Barcelona Clinic Liver Cancer-B patients.
|
31606196 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The colorimetric immunoassay showed a linear relationship with the liver cancer marker (α-fetoprotein, AFP) in the range of 0.1-10 000 ng/mL with the detection limit of 0.46 ng/mL.
|
31074952 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver cancer dedifferentiation markers (AFP, CD133, EPCAM, and KRT19) were found to be progressively increased while hepatocyte terminal differentiation markers (ALB, G6PC, CYP3A4, and HNF4A) were progressively decreased from HCC patients with low SOX signature scores to patients with high SOX signature scores.
|
31462277 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Cox regression model revealed that liver cancer survival was independently associated with tumor size, metastasis and α-fetoprotein value.
|
31452799 |
2019 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, analyzing data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) and GSE14520 datasets revealed a significant correlation between MED15 expression and the tumor size (P=0.033), Barcelona Clinic Liver Cancer stage (P=0.031), α-fetoprotein levels (P=0.002) and metastasis risk (P=0.001).
|
29556287 |
2018 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prognostic value of PFS and OS-pPET-RadScore, Barcelona-Clinic Liver Cancer staging system and serum alpha-fetoprotein level was analyzed to predict PFS and OS in multivariate analysis.
|
29435123 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy.
|
29805966 |
2018 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conversely, higher Child-Pugh class, alpha-fetoprotein levels over 400 kU/L, and later BCLC disease stages were each associated with higher mortality.
|
30309301 |
2018 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The 20-week survival rate of DEN-induced liver cancer rats administered with oral 1,4-GL was increased from 45.0 to 70.0% with reduced carcinogenesis of the liver and significantly lowered serum α-fetoprotein level (14.28 ± 2.89 ng/mL vs. 18.56 ± 4.65 ng/mL, p = 0.012).
|
31070541 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conductometric immunoassay of alpha-fetoprotein in sera of liver cancer patients using bienzyme-functionalized nanometer-sized silica beads.
|
30398232 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ultrasensitive Detection of Serum MicroRNA Using Branched DNA-Based SERS Platform Combining Simultaneous Detection of α-Fetoprotein for Early Diagnosis of Liver Cancer.
|
30238748 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alpha fetoprotein assessment by using a nano optical sensor thin film binuclear Pt-2-aminobenzimidazole-Bipyridine for early diagnosis of liver cancer.
|
29784373 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to the small risk of liver cancer development, screening for liver cancer (especially HCC) is still recommended in HT1 patients using regular measures of α-fetoprotein and imaging.
|
28755188 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate and multivariate analyses revealed the SHI was an independent predictor for overall survival and relapse-free survival, and prognostic for patients with negative α-fetoprotein and Barcelona Clinic Liver Cancer stage 0+A.
|
28769812 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFP is an important target in the treatment of liver cancer.
|
28554567 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Best performance was found for CEA in colorectal cancer (area under the curve=0.84, sensitivity=51.7% at 95% specificity vs. benign), CA19-9 in gallbladder/pancreatic cancer (AUC=0.85, sensitivity=60.6%) and AFP in liver cancer (AUC=0.87, sensitivity=68.4%).
|
28011514 |
2017 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.
|
27925189 |
2017 |